Results 41 to 50 of about 22,643,381 (355)

Prophylaxis in Hemophilia

Clinical and Biomedical Research, 2023
Hemophilia is an inherited X-linked coagulopathy defined by a deficiency or abnormality in the clotting function of factor VIII (Hemophilia A) or factor IX (Hemophilia B).
Júlia Plentz Portich, Dayenne Catelli, Ebellins Tabares Calvache, Cristiane Seganfredo Weber, Daniel Sander Hoffmann, Guilherme Rasia Bosi, Leo Sekine, Lucia Mariano da Rocha Silla   +7 more
doaj  

Hemophilia A gene therapy: current and next-generation approaches

Expert Opinion on Biological Therapy, 2021
Introduction Hemophilia comprises a group of X-linked hemorrhagic disorders that result from a deficiency of coagulation factors. The disorder affects mainly males and leads to chronic pain, joint deformity, reduced mobility, and increased mortality ...
S. Pipe, Gil Gonen-Yaacovi, O. Segurado
semanticscholar   +1 more source

Hemophilia: a biography on therapeutical approaches

Clinical and Biomedical Research, 2023
The history of hemophilia is ancient, with descriptions dated to the 2nd century AD. The first modern narratives appeared in 1800s, when total blood transfusion was the only available treatment and life expectancy was remarkably low.
Dayenne Catelli, Júlia Plentz Portich, Ebellins Tabares Calvache, Cristiane Seganfredo Weber, Daniel Sander Hoffmann, Guilherme Rasia Bosi, Leo Sekine, Lucia Mariano da Rocha Silla   +7 more
doaj  

Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

New England Journal of Medicine, 2018
BACKGROUND Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis.
J. Mahlangu, J. Oldenburg, I. Paz‐Priel, C. Négrier, M. Niggli, E. Mancuso, C. Schmitt, V. Jiménez‐Yuste, C. Kempton, C. Dhalluin, M. Callaghan, W. Buján, M. Shima, J. Adamkewicz, E. Asikanius, G. Levy, R. Kruse-Jarres   +16 more
semanticscholar   +1 more source

BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.

New England Journal of Medicine, 2020
BACKGROUND Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients' quality of life. The half-life of recombinant factor VIII ranges from 15 to 19 hours because
B. Konkle, A. Shapiro, D. Quon, J. Staber, R. Kulkarni, M. Ragni, E. S. Chhabra, S. Poloskey, K. Rice, S. Katragadda, J. Fruebis, C. Benson   +11 more
semanticscholar   +1 more source

Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophilia—Hematology Utilization Group Study Part VII (HUGS VII)

Journal of Blood Medicine, 2022
Randall Curtis,1 Marilyn Manco-Johnson,2 Barbara A Konkle,3 Roshni Kulkarni,4 Joanne Wu,5 Judith R Baker,6 Megan Ullman,7 Duc Quang Tran Jr,8 Michael B Nichol5 1Factor VIII Computing, Berkeley, CA, USA; 2Hemophilia and Thrombosis Center, University of ...
Curtis R, Manco-Johnson M, Konkle BA, Kulkarni R, Wu J, Baker JR, Ullman M, Tran DQ Jr, Nichol MB   +8 more
doaj  

Developing BIVV001, a new class of factor VIII replacement for hemophilia A that is von Willebrand factor-independent.

Blood, 2020
Factor VIII (FVIII) replacement products enable comprehensive care in hemophilia A. Treatment goals in severe hemophilia A are expanding beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII levels.
Ekta Seth Chhabra, Tongyao Liu, J. Kulman, Susannah L Patarroyo-White, Buyue Yang, Qi Lu, Douglas Drager, Nancy Moore, Jiayun Liu, Amy M. Holthaus, J. Sommer, Ayman Ismail, Deana Rabinovich, Zhan Liu, A. van der Flier, A. Goodman, Christopher M. Furcht, Mark Tié, Tyler Carlage, R. Mauldin, Terrence M. Dobrowsky, Z. Liu, Oblaise A. Mercury, Lily Zhu, B. Mei, V. Schellenberger, Haiyan Jiang, G. Pierce, Joe Salas, R. Peters   +29 more
semanticscholar   +1 more source

Hemophilia management: Huge impact of a tiny difference

Research and Practice in Thrombosis and Haemostasis, 2020
Hemophilia A and B are inherited X‐linked disorders of hemostasis, associated with an increased bleeding tendency. Patients with severe hemophilia have undetectable clotting factor levels and experience spontaneous bleeds.
Fabienne Kloosterman, Anne‐Fleur Zwagemaker, Amal Abdi, Samantha Gouw, Giancarlo Castaman, Karin Fijnvandraat   +5 more
doaj   +1 more source

Hemophilia A Resulting in Severe Hyperesthesia Due to Extraparenchymal Spinal Cord Hemorrhage in a Young Golden Retriever Puppy

Veterinary Sciences, 2022
A ten-week-old male Golden retriever puppy was presented with severe hyperesthesia, mild neurological deficits and episcleral bleeding. Clotting times showed a normal prothrombin time (PT) and prolonged activated partial thromboplastin time (aPPT ...
Charlotte Lubbers, Martijn Beukers, Niklas Bergknut, Geert Paes   +3 more
doaj   +1 more source

"Prevalence of inhibitors in a population of 1280 Hemophilia A patients in Iran " [PDF]

Acta Medica Iranica, 2003
Development of inhibitor to factor VIII is the most serious complication of hemophilia therapy. To determine the prevalence of inhibitors in Iran hemophilia A patients exposed to blood products, 1280 hemophilia A patients (age range 9 months-84 years ...
Sharifian R, Hosseini M, Safai R, Tugeh Gh, Ehsani AH, Lak M, Jazebi M   +6 more
doaj   +2 more sources